Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00419393 · ClinicalTrials.gov registry record · Phase 3
Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures
A Phase 3 study of Epilepsy, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 190
- Enrollment target
- 20
- Study locations
NCT00419393: Completed Phase 3 study of Epilepsy, sponsored by UCB Pharma.
NCT00419393 is a Phase 3 study of Epilepsy that has completed, run by UCB Pharma. The registered enrollment target is 190 participants, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00419393, a Phase 3 study of Epilepsy, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 190 participants
- Enrollment target
- 20
- Study locations
Study Summary
To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.
Primary Outcome
An adverse event is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Conditions Studied
Interventions
- DRUG Keppra XR (Levetiracetam XR)
Study Locations (20)
Other
- - Aguascalientes
- - Guadalajara
- - Guadalajara Jalisco
- - Mexico City
Alabama
- - Dothan
- - Northport
Georgia
- - Atlanta
- - Suwanee
New York
- - Buffalo
- - Cedarhurst
Arizona
- - Phoenix
Arkansas
- - Little Rock
California
- - Bakersfield
Florida
- - Loxahatchee Groves
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 190 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-03 |
| Phase | Phase 3 |
What the finished NCT00419393 record still lists
NCT00419393 is an interventional study that assigns participants to a tested intervention. The registered 190 participants enrollment target is mid-sized for trials with a published cap, below the 951-participant average among 160 other Epilepsy trials with a reported enrollment target (80% lower).
The record links to 1 condition, with Epilepsy appearing as the primary indexed condition, and to 1 intervention - of which Keppra XR (Levetiracetam XR) is the first listed.
NCT00419393 names 20 study sites across 14 states, led by Other, Alabama, Georgia.
Frequently Asked Questions
What is clinical trial NCT00419393 about?
NCT00419393 is a clinical study titled "Long Term Follow-up Study With Keppra XR (Levetiracetam XR) for Partial Seizures". To provide continued treatment of Keppra XR (Levetiracetam XR) and to assess the long term safety of Keppra XR in subjects with partial onset seizures.
What is the current status of trial NCT00419393?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 190 participants. The study started on 2007-12. Estimated completion is 2010-03.
What conditions does trial NCT00419393 study?
This clinical trial studies the following conditions: Epilepsy.
What interventions are being tested in trial NCT00419393?
The interventions under investigation include: Keppra XR (Levetiracetam XR) (DRUG).
Who is sponsoring clinical trial NCT00419393?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00419393 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Epilepsy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00419393's enrollment target sits among peer trials
190 34th of 160 higher than 126 of 160 other Epilepsy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Epilepsy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures
RECRUITING · Phase 3
-
Lemborexant Treatment of Insomnia Linked to Epilepsy
RECRUITING · Phase 3
-
RNS System NAUTILUS Study
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
COMPLETED · Phase 3
-
Clobazam in Patients With Lennox-Gastaut Syndrome
COMPLETED · Phase 3
-
Pediatric Epilepsy Study
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03257033 · 190 participants · Phase 3
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
- NCT03642028 · 190 participants · Phase 4
Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance in Posttraumatic Stress
- NCT04015609 · 190 participants · NA
Psychotherapy Intervention for Latinos With Advanced Cancer
- NCT04284397 · 190 participants · Early Phase 1
Identification of Critical Thermal Environments for Aged Adults
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia